Last updated: November 7, 2023
Sponsor: Tanta University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Migraine And Cluster Headaches
Oral Facial Pain
Migraine (Pediatric)
Treatment
Medical Treatment
Greater Occipital Nerve Block
bupivacaine or onabotulinum toxin A injection.
Clinical Study ID
NCT06122545
35459/4/22
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age > 18 years old.
- Both sexes.
- Patients with chronic migraine.
Exclusion
Exclusion Criteria:
- Age less than 18 years.
- Patients with medication overuse headache.
- Patients who had used acute pain medications within 24 hours prior to the study visit.
- History of injury to the area of the GON.
- Any prior adverse reactions to local anesthetics.
- Patients with impaired sensation in the occipital area.
- Any neurological or dermatological disease that may have affected skin sensation,bleeding tendency, any skull defect.
Study Design
Total Participants: 80
Treatment Group(s): 3
Primary Treatment: Medical Treatment
Phase:
Study Start date:
May 01, 2022
Estimated Completion Date:
May 01, 2024
Study Description
Connect with a study center
Tanta University
Tanta, El-Gharbia 31527
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.